A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

Recruiting

Phase 2

Fianlimab, Cemiplimab, IpilimumabA Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT06594991

Conditions

Advanced Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Fianlimab

Cemiplimab

Ipilimumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2025-01-07.